PE20060657A1 - Derivados de pirimidina como moduladores de ppar-alfa - Google Patents
Derivados de pirimidina como moduladores de ppar-alfaInfo
- Publication number
- PE20060657A1 PE20060657A1 PE2005001101A PE2005001101A PE20060657A1 PE 20060657 A1 PE20060657 A1 PE 20060657A1 PE 2005001101 A PE2005001101 A PE 2005001101A PE 2005001101 A PE2005001101 A PE 2005001101A PE 20060657 A1 PE20060657 A1 PE 20060657A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- methyl
- phenyl
- ppar
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE PIRIMIDINA DE FORMULA I, DONDE A ES O O S; UNO DE LOS MIEMBROS DE ANILLO D Y E REPRESENTA N Y EL OTRO CH; Z ES (CH2)m, O O N-R9; m ES 0, 1 O 2; R9 ES H O ALQUILO C1-C6; n ES 0, 1 O 2; R1 ES ARILO C6-C10 O HETEROARILO DE 5 A 10 MIEMBROS QUE PUEDE ESTAR SUSTITUIDO POR HALOGENO, CIANO, ALQUILO C1-C6, ENTRE OTROS; R10 ES H, ALQUILO C1-C6, FENILO, ENTRE OTROS; R11 ES H, ALQUILO C1-C6, FENILO, ENTRE OTROS; R2 ES H, ARILO C6-C10, ALQUENILO C2-C6, ENTRE OTROS; R3 Y R4 SON H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R5 Y R6 SON H, ALQUILO C1-C6, FENOXI, ENTRE OTROS; R7 ES -NHR16 U -OR17; R16 ES H O ALQUILO C1-C4; R17 ES H O UN GRUPO HIDROLIZABLE, QUE PUEDE SER TRANSFORMADO EN EL ACIDO CARBOXILICO CORRESPONDIENTE; R8 ES H O METILO. SON COMPUESTOS PREFERIDOS: ACIDO 2-({4-[((2-FURILMETIL){[6-(4-METILFENIL)-PIRIMIDIN-4-IL]-METIL}-AMINO)METIL]-FENIL}-TIO)-2-METILPROPANOICO, CLORHIDRATO DE ACIDO 2-({4-[((2-FURILMETIL){[6-(3-TRIFLUOROMETILFENIL)PIRIMIDIN-4-IL]METIL}AMINO)METIL]FENIL}TIO)-2-METILPROPANOICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION . DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR ALFA ACTIVADO POR INDUCTORES DE LA PRODUCCION DE PEROXISOMAS (PPAR-ALFA) Y SON UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE ENFERMEDADES CARDIOVASCULARES, PARTICULARMENTE DISLIPIDEMIAS, ARTERIOSCLEROSIS, INSUFICIENCIA CARDIACA, TROMBOSIS Y TRASTORNOS METABOLICOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004046623A DE102004046623A1 (de) | 2004-09-25 | 2004-09-25 | Neue Pyrimidin-Derivate und ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060657A1 true PE20060657A1 (es) | 2006-08-12 |
Family
ID=35063041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001101A PE20060657A1 (es) | 2004-09-25 | 2005-09-23 | Derivados de pirimidina como moduladores de ppar-alfa |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20080261990A1 (es) |
| EP (1) | EP1797045A1 (es) |
| JP (1) | JP2008514559A (es) |
| KR (1) | KR20070055621A (es) |
| CN (1) | CN101065364A (es) |
| AR (1) | AR051295A1 (es) |
| AU (1) | AU2005287589A1 (es) |
| BR (1) | BRPI0517327A (es) |
| CA (1) | CA2582492A1 (es) |
| DE (1) | DE102004046623A1 (es) |
| EC (1) | ECSP077340A (es) |
| GT (1) | GT200500266A (es) |
| IL (1) | IL182136A0 (es) |
| MA (1) | MA28882B1 (es) |
| MX (1) | MX2007003428A (es) |
| NO (1) | NO20072051L (es) |
| PE (1) | PE20060657A1 (es) |
| RU (1) | RU2007115215A (es) |
| SV (1) | SV2007002235A (es) |
| TW (1) | TW200628451A (es) |
| UY (1) | UY29127A1 (es) |
| WO (1) | WO2006032384A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009010953A (es) * | 2007-04-13 | 2009-10-29 | Millenium Pharmaceuticals Inc | Terapia anticoagulante en combinacion, con un compuesto que actua como un inhibidor del factor xa. |
| KR100813387B1 (ko) * | 2007-06-26 | 2008-03-12 | 신명곤 | 부형제 첨가없이 인삼농축액으로 유동성 및 저장성이우수한 인삼농축액환 제조 방법 |
| EP3593802A3 (en) | 2010-05-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| US20130197043A1 (en) | 2010-08-31 | 2013-08-01 | Snu R&Db Foundation | Use of the fetal reprogramming of a ppar agonist |
| SG10201406155QA (en) | 2011-10-28 | 2014-11-27 | Lumena Pharmaceuticals Inc | Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases |
| MX369466B (es) | 2011-10-28 | 2019-11-08 | Lumena Pharmaceuticals Inc | Inhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas. |
| CN103130732A (zh) * | 2011-11-22 | 2013-06-05 | 上海博康精细化工有限公司 | 3,5-二甲基-4-氯甲基异噁唑的制备方法 |
| MX2015013193A (es) | 2013-03-15 | 2016-04-15 | Lumena Pharmaceuticals Inc | Inhibidores del reciclaje de acidos biliares para el tratamiento de colangitis esclerosante primaria y enfermedad inflamatoria intestinal. |
| WO2014144485A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease |
| WO2017190050A1 (en) * | 2016-04-28 | 2017-11-02 | Cornell University | Inhibitors of soluble adenylyl cyclase |
| US20220152022A1 (en) | 2019-02-12 | 2022-05-19 | Mirum Pharmaceuticals, Inc. | Methods for increasing growth in pediatric subjects having cholestatic liver disease |
| CN115598267B (zh) * | 2022-12-13 | 2023-05-09 | 山东省食品药品检验研究院 | 一种格列齐特中潜在遗传毒性杂质的分析方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU72201A (sh) * | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
| GB0214254D0 (en) * | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
-
2004
- 2004-09-25 DE DE102004046623A patent/DE102004046623A1/de not_active Withdrawn
-
2005
- 2005-09-10 MX MX2007003428A patent/MX2007003428A/es not_active Application Discontinuation
- 2005-09-10 JP JP2007532798A patent/JP2008514559A/ja active Pending
- 2005-09-10 EP EP05782757A patent/EP1797045A1/de not_active Withdrawn
- 2005-09-10 WO PCT/EP2005/009734 patent/WO2006032384A1/de active Application Filing
- 2005-09-10 CN CNA2005800404273A patent/CN101065364A/zh active Pending
- 2005-09-10 BR BRPI0517327-2A patent/BRPI0517327A/pt not_active Application Discontinuation
- 2005-09-10 US US11/663,813 patent/US20080261990A1/en not_active Abandoned
- 2005-09-10 RU RU2007115215/04A patent/RU2007115215A/ru not_active Application Discontinuation
- 2005-09-10 KR KR1020077009268A patent/KR20070055621A/ko not_active Application Discontinuation
- 2005-09-10 AU AU2005287589A patent/AU2005287589A1/en not_active Abandoned
- 2005-09-10 CA CA002582492A patent/CA2582492A1/en not_active Abandoned
- 2005-09-20 AR ARP050103930A patent/AR051295A1/es unknown
- 2005-09-23 TW TW094132926A patent/TW200628451A/zh unknown
- 2005-09-23 SV SV2005002235A patent/SV2007002235A/es not_active Application Discontinuation
- 2005-09-23 GT GT200500266A patent/GT200500266A/es unknown
- 2005-09-23 PE PE2005001101A patent/PE20060657A1/es not_active Application Discontinuation
- 2005-09-23 UY UY29127A patent/UY29127A1/es not_active Application Discontinuation
-
2007
- 2007-03-22 IL IL182136A patent/IL182136A0/en unknown
- 2007-03-23 EC EC2007007340A patent/ECSP077340A/es unknown
- 2007-03-30 MA MA29787A patent/MA28882B1/fr unknown
- 2007-04-20 NO NO20072051A patent/NO20072051L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0517327A (pt) | 2008-10-07 |
| NO20072051L (no) | 2007-06-07 |
| WO2006032384A1 (de) | 2006-03-30 |
| SV2007002235A (es) | 2007-03-20 |
| US20080261990A1 (en) | 2008-10-23 |
| AU2005287589A1 (en) | 2006-03-30 |
| MA28882B1 (fr) | 2007-09-03 |
| CN101065364A (zh) | 2007-10-31 |
| CA2582492A1 (en) | 2006-03-30 |
| IL182136A0 (en) | 2007-07-24 |
| UY29127A1 (es) | 2006-04-28 |
| DE102004046623A1 (de) | 2006-03-30 |
| KR20070055621A (ko) | 2007-05-30 |
| GT200500266A (es) | 2006-05-11 |
| ECSP077340A (es) | 2007-04-26 |
| RU2007115215A (ru) | 2008-11-10 |
| EP1797045A1 (de) | 2007-06-20 |
| MX2007003428A (es) | 2008-03-13 |
| JP2008514559A (ja) | 2008-05-08 |
| AR051295A1 (es) | 2007-01-03 |
| TW200628451A (en) | 2006-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060657A1 (es) | Derivados de pirimidina como moduladores de ppar-alfa | |
| AR038419A1 (es) | Derivados de piridina y quinolina | |
| PE20061353A1 (es) | Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa | |
| PE20120399A1 (es) | Derivados del l-(piperidin-4-il)-pirazol como moduladores de gpr 119 | |
| PE20060336A1 (es) | Compuestos derivados de 1-amino-ftalazina como moduladores de mch1 | |
| PE20091376A1 (es) | Derivados de fenilamino como moduladores de beta-amiloide | |
| PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
| PE20021152A1 (es) | Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma | |
| AR061644A1 (es) | Derivados de benzofurano | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| AR064459A1 (es) | Derivados de sulfonamida | |
| PE20050132A1 (es) | Piperazinas heterociclicas sustituidas | |
| PE20080772A1 (es) | Nuevos derivados de bipiridina sustituidos y su uso | |
| CO5690643A2 (es) | Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos | |
| PE20060357A1 (es) | Compuestos y composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| PE20061348A1 (es) | DERIVADOS DEL ACIDO PIRMIDINCARBOXILICO COMO MODULADORES DE PPAR-alfa | |
| PE20080843A1 (es) | Inhibidores de renina y metodo para su utilizacion | |
| NO20050429L (no) | Substituert kinolin-CCR5-reseptorantagonister | |
| PE20080091A1 (es) | Derivados de cicloalquilamino como agentes moduladores de s1p | |
| PE20110196A1 (es) | 5-alquinil-pirimidinas | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| PE20070550A1 (es) | Derivados de la 1-amino-ftalazina sustituida afines al receptor mch1 y su preparacion | |
| PE20060881A1 (es) | Sulfonamido-macrociclos y sus sales como inhibidores de tie2 y composiciones farmaceuticas que comprenden estos compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |